160 related articles for article (PubMed ID: 22773822)
1. Initiation of adjuvant hormone therapy by Medicaid insured women with nonmetastatic breast cancer.
Yung RL; Hassett MJ; Chen K; Gesten FC; Roohan PJ; Boscoe FP; Sinclair AH; Schymura MJ; Schrag D
J Natl Cancer Inst; 2012 Jul; 104(14):1102-5. PubMed ID: 22773822
[TBL] [Abstract][Full Text] [Related]
2. Racial differences in receipt of adjuvant hormonal therapy among Medicaid enrollees in South Carolina diagnosed with breast cancer.
Felder TM; Do DP; Lu ZK; Lal LS; Heiney SP; Bennett CL
Breast Cancer Res Treat; 2016 May; 157(1):193-200. PubMed ID: 27120468
[TBL] [Abstract][Full Text] [Related]
3. High Initiation of Adjuvant Hormonal Therapy Among Uninsured Stages I-III Breast Cancer Patients Treated in a Safety-Net Healthcare System.
Murphy CC; Tiro JA; Jean GW; Balasubramian BA; Alvarez CA
J Womens Health (Larchmt); 2017 Jun; 26(6):655-661. PubMed ID: 28296574
[TBL] [Abstract][Full Text] [Related]
4. Association of Adjuvant Hormone Therapy Timing With Overall Survival Among Patients With Hormone Receptor-Positive Human Epidermal Growth Factor Receptor-2-Negative Early Breast Cancer Without Chemotherapy.
Fu F; Yu L; Zeng B; Chen M; Guo W; Chen L; Lin Y; Hou J; Li J; Li Y; Li S; Chen X; Zhang W; Jin X; Cai W; Zhang K; Chen H; Qiu Y; Nie Q; Wang C; Jacobs L
JAMA Netw Open; 2022 Feb; 5(2):e2145934. PubMed ID: 35166783
[TBL] [Abstract][Full Text] [Related]
5. Association between financial burden and adjuvant hormonal therapy adherence and persistent use for privately insured women aged 18-64 years in BCBS of Texas.
Kim J; Rajan SS; Du XL; Franzini L; Giordano SH; Morgan RO
Breast Cancer Res Treat; 2018 Jun; 169(3):573-586. PubMed ID: 29423900
[TBL] [Abstract][Full Text] [Related]
6. Prescription Patterns, Initiation, and 5-Year Adherence to Adjuvant Hormonal Therapy Among Commercially Insured Patients With Breast Cancer.
Zhao H; Lei X; Niu J; Zhang N; Duan Z; Chavez-MacGregor M; Giordano SH
JCO Oncol Pract; 2021 Jun; 17(6):e794-e808. PubMed ID: 33596096
[TBL] [Abstract][Full Text] [Related]
7. Racial/ethnic differences in initiation of adjuvant hormonal therapy among women with hormone receptor-positive breast cancer.
Livaudais JC; Hershman DL; Habel L; Kushi L; Gomez SL; Li CI; Neugut AI; Fehrenbacher L; Thompson B; Coronado GD
Breast Cancer Res Treat; 2012 Jan; 131(2):607-17. PubMed ID: 21922245
[TBL] [Abstract][Full Text] [Related]
8. Risk of Recurrence or Contralateral Breast Cancer More than 5 Years After Diagnosis of Hormone Receptor-Positive Early-Stage Breast Cancer.
Wilson S; Speers C; Tyldesley S; Chia S; Kennecke H; Ellard S; Lohrisch C
Clin Breast Cancer; 2016 Aug; 16(4):284-90. PubMed ID: 26705158
[TBL] [Abstract][Full Text] [Related]
9. Impact of high-deductible insurance on adjuvant hormonal therapy use in breast cancer.
Lu CY; Zhang F; Wagner AK; Nekhlyudov L; Earle CC; Callahan M; LeCates R; Xu X; Ross-Degnan D; Wharam JF
Breast Cancer Res Treat; 2018 Aug; 171(1):235-242. PubMed ID: 29754304
[TBL] [Abstract][Full Text] [Related]
10. Geographic disparities in adherence to adjuvant endocrine therapy in Appalachian women with breast cancer.
Tan X; Camacho F; Marshall VD; Donohoe J; Anderson RT; Balkrishnan R
Res Social Adm Pharm; 2017; 13(4):796-810. PubMed ID: 27641308
[TBL] [Abstract][Full Text] [Related]
11. A Prospective Comparison of Younger and Older Patients' Preferences for Adjuvant Chemotherapy and Hormonal Therapy in Early Breast Cancer.
Hamelinck VC; Bastiaannet E; Pieterse AH; de Glas NA; Portielje JE; Merkus JW; den Hoed ID; van de Velde CJ; Liefers GJ; Stiggelbout AM
Clin Breast Cancer; 2016 Oct; 16(5):379-388. PubMed ID: 27212474
[TBL] [Abstract][Full Text] [Related]
12. 5-year adherence to adjuvant endocrine treatment in Dutch women with early stage breast cancer: A population-based database study (2006-2016).
van den Biggelaar YJPG; Kuiper JG; van der Sangen MJC; Luiten EJT; Siesling S; van Herk-Sukel M; Voogd AC; Mesters I
Breast Dis; 2023; 42(1):331-339. PubMed ID: 37927248
[TBL] [Abstract][Full Text] [Related]
13. Adjuvant hormonal therapy use among insured, low-income women with breast cancer.
Kimmick G; Anderson R; Camacho F; Bhosle M; Hwang W; Balkrishnan R
J Clin Oncol; 2009 Jul; 27(21):3445-51. PubMed ID: 19451445
[TBL] [Abstract][Full Text] [Related]
14. Adjuvant radiation with hormonal therapy is associated with improved survival in men with pathologically involved lymph nodes after radical surgery for prostate cancer.
Wong AT; Schwartz D; Osborn V; Safdieh J; Weiner J; Schreiber D
Urol Oncol; 2016 Dec; 34(12):529.e15-529.e20. PubMed ID: 27443637
[TBL] [Abstract][Full Text] [Related]
15. Racial and geographic disparities in adherence and discontinuation to adjuvant endocrine therapy in Texas Medicaid-insured patients with breast cancer.
Farias AJ; Wu WH; Du XL
Med Oncol; 2018 Jun; 35(7):113. PubMed ID: 29926275
[TBL] [Abstract][Full Text] [Related]
16. Treatment Disparities in Radiation and Hormone Therapy Among Women Covered by Medicaid vs Private Insurance in Cancer Registry and Claims Data.
Bradley CJ; Sabik LM; Liang R; Lindrooth RC; Perraillon MC
JAMA Health Forum; 2023 May; 4(5):e230673. PubMed ID: 37145688
[TBL] [Abstract][Full Text] [Related]
17. Association of Endocrine Therapy Initiation Timeliness With Adherence and Continuation in Low-Income Women With Breast Cancer.
Sood N; Liu Y; Lian M; Greever-Rice T; Lucht J; Schmaltz C; Colditz GA
JAMA Netw Open; 2022 Aug; 5(8):e2225345. PubMed ID: 35921108
[TBL] [Abstract][Full Text] [Related]
18. Endocrine therapy initiation among Medicaid-insured breast cancer survivors with hormone receptor-positive tumors.
Wheeler SB; Kohler RE; Reeder-Hayes KE; Goyal RK; Lich KH; Moore A; Smith TW; Melvin CL; Muss HB
J Cancer Surviv; 2014 Dec; 8(4):603-10. PubMed ID: 24866922
[TBL] [Abstract][Full Text] [Related]
19. Effect of delays in initiation of adjuvant endocrine therapy on survival among women with breast cancer.
Lee KT; Jacobs L; Walsh EM; Stearns V; Segal JB
Breast Cancer Res Treat; 2020 Dec; 184(3):965-975. PubMed ID: 32914353
[TBL] [Abstract][Full Text] [Related]
20. Use and Effectiveness of Adjuvant Endocrine Therapy for Hormone Receptor-Positive Breast Cancer in Men.
Venigalla S; Carmona R; Guttmann DM; Jain V; Freedman GM; Clark AS; Shabason JE
JAMA Oncol; 2018 Oct; 4(10):e181114. PubMed ID: 29800030
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
